Viral manufacturer Vibalogics plots out expansion at German site as US growth plans are underway
A German CDMO specializing in viral manufacturing is expanding its operations in Europe by building out an existing plant — and soon, it will be its own landlord, too.
Vibalogics has begun the first stage of a $50 million expansion of its Cuxhaven, Germany facility, the company announced. It will also buy the site outright from the current owner.
The CDMO specializes in the production of oncolytic viruses and viral vector-based vaccines and gene therapy products. The expansion will add another 100,000 square feet at the site for quality batch release and stability studies, drug product fill-finish and process development.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 113,500+ biopharma pros reading Endpoints daily — and it's free.